Boston Scientific, a biotechnology/biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialities, also a global leader in cardiovascular medicine is one of the world’s largest medical device companies. In a path breaking discovery, recently Boston Scientific introduced Eluvia drug-eluting vascular stent system as a drug delivery device for the treatment of peripheral artery disease (PAD).
Eluvia has a hydrophobic promus polymer which protects the drug from dissolving in the blood and allows for highly controlled drug delivery to the target lesion. Eluvia uses a drug polymer combination to deliver the chemotherapy drug paclitaxel over a period of one year. Observation reveals that Eluvia reduces downstream particulates and has low systemic drug exposure with no measurable levels of paclitaxel in the bloodstream within thirty minutes.
The one year long clinical trial demonstrated superiority of the Eluvia stent compared to self- expanding bare metal stents for the treatment of peripheral artery disease (PAD) and superficial femoral artery (SFA) or popliteal artery (PPA) lesions up to 210mm in length. There were 775 patients involved in the trial, making it the largest randomized trial of a drug-eluting stent for the treatment of PAD till date. Eluvia stent showed superiority with a primary patency rate of 85.4% as compared to 76.3% with BMS. Eluvia stent which does sustained release of the lowest dose of paclitaxel of any peripheral drug-eluting device, re-opens blocked arteries and restores blood flow along with using a drug-polymer combination to prevent tissue regrowth.